Clorofilla Srl has taken part with enthusiasm in Probiotic Value Insights, the new IPA Europe initiative designed to bring the scientific, health and socio-economic value of probiotics into a broader public and policy conversation. Working alongside IPA Europe, Clorofilla contributed to the development of the dedicated website and to the communication strategy behind the project, with the aim of making complex scientific and economic evidence more accessible to policymakers, healthcare stakeholders, researchers, industry representatives and the wider public.

The initiative marks an important step for the European probiotic sector. Rather than focusing only on probiotics as products, Probiotic Value Insights frames them within a wider discussion on prevention, healthcare sustainability, quality of life and innovation. At the centre of the platform is the Socio-Economic Impact Assessment on Probiotics in Europe, commissioned by IPA Europe and conducted using recognised OECD and EU Better Regulation methodologies.

The message emerging from the assessment is clear: even small improvements in health outcomes at population level can generate substantial benefits for society. According to the analysis, a 1% improvement in probiotic use across seven major health areas could generate at least €10 billion in annual socio-economic benefits in Europe. These benefits would come mainly from reduced healthcare costs and increased productivity linked to better health outcomes.

From microbiome science to socio-economic value

Probiotics are among the most widely available microbiome-based interventions today. They are consumed through fermented foods, dairy products and food supplements, and are supported by a growing body of scientific evidence in specific health applications. However, the public health and economic implications of their use have often remained underexplored or fragmented across different fields of research.

Probiotic Value Insights seeks to address this gap by bringing together scientific evidence, socio-economic data and educational resources in one dedicated platform. The website provides access to the full assessment, executive summaries, policy recommendations, scientific resources, videos, infographics and media materials. It is intended not only as an information repository, but as a learning hub to support informed dialogue around probiotics, prevention and public health in Europe.

The platform focuses on seven high-burden health domains: antibiotic use and gut health, respiratory infections, lactose digestion, women’s reproductive health, bowel function, oral health and mental well-being through the gut-brain axis. These areas were selected because they are highly prevalent, carry a significant burden for healthcare systems and society, and are supported by relevant evidence on the potential contribution of specific probiotic applications.

In antibiotic-associated diarrhoea, for example, the platform highlights the role of probiotics in supporting gut microbiota balance during antibiotic use. In respiratory health, it explores the potential contribution of probiotics in reducing the incidence, duration and severity of respiratory infections. Other sections address lactose intolerance, recurrent bacterial vaginosis, constipation, oral microbiota balance and the emerging relationship between the gut microbiome and mental well-being.

A public health perspective on probiotics

One of the most relevant aspects of the initiative is its attempt to move the conversation beyond individual product benefits. The SEA suggests that probiotics may contribute to broader public health goals by supporting prevention-oriented strategies in common conditions that affect millions of people across Europe.

This is particularly important at a time when European healthcare systems are under increasing pressure from ageing populations, chronic conditions, recurrent infections and rising healthcare costs. In this context, interventions that are already available, relatively accessible and supported by scientific evidence may deserve greater attention within prevention and health promotion strategies.

The assessment does not present probiotics as a substitute for medical care, nor as a universal solution. Instead, it positions them as one component of a broader approach to health, nutrition and prevention. This distinction is essential. The value of probiotics depends on the use of scientifically characterised strains, administered in adequate amounts and applied in appropriate health contexts.

For IPA Europe, the findings also point to the need for a more coherent European framework. While consumer interest in probiotics continues to grow, the EU still lacks a harmonised definition and regulatory approach for probiotic foods and food supplements. This creates uncertainty for consumers, healthcare professionals, authorities and companies, and may limit the ability to communicate science-based information clearly.

The regulatory and innovation challenge

Europe already has a strong scientific and industrial foundation in probiotics. The European probiotic market has grown steadily in recent years and is expected to continue expanding, driven by consumer demand for gut health, immune support and microbiome-related products. Yet the absence of a harmonised EU-wide approach remains a major issue.

According to the initiative, clearer definitions, labelling standards and communication rules could support consumer trust, responsible innovation and market competitiveness. This is particularly relevant when compared with other regions, including the United States, Canada and parts of Asia, where probiotic definitions and health-claim frameworks are more clearly established.

Probiotic Value Insights therefore also has a policy dimension. By translating scientific and economic data into accessible formats, the platform aims to support a more constructive discussion on how Europe can better integrate microbiome science into public health strategies. Regulatory clarity, in this perspective, is not only an industry concern. It is also linked to consumer information, healthcare sustainability and Europe’s ability to remain competitive in a rapidly evolving field.

A platform for evidence, dialogue and prevention

The launch of Probiotic Value Insights comes at a time when the microbiome is increasingly recognised as a key interface between nutrition, health and disease prevention. For years, scientific research has shown that the gut microbiota and other microbial ecosystems play an important role in digestion, immune function, metabolic balance and communication between body systems. The challenge now is to translate this knowledge into practical, evidence-based strategies that can benefit citizens and healthcare systems.

This is where the platform may play a useful role. By combining the full SEA report with infographics, slide decks and domain-specific summaries, Probiotic Value Insights offers different entry points for different audiences. Policymakers can access economic arguments and policy recommendations. Healthcare stakeholders can explore the evidence across specific health areas. Industry representatives can better understand the link between innovation, regulation and public health. Consumers can find clearer information on why probiotics matter and how they fit within a broader vision of nutrition and prevention.

For Clorofilla, contributing to this project has meant supporting an initiative that aligns closely with its mission: improving the quality of scientific communication and helping evidence-based knowledge reach the audiences that can act on it. In the case of probiotics, this means helping shift the discussion from isolated product claims to a broader understanding of value: scientific, societal, economic and health-related.

The central question raised by the initiative is simple but powerful: what if small improvements in health, achieved at population level, could deliver major benefits for society?

Probiotic Value Insights does not claim that probiotics alone can solve Europe’s healthcare challenges. But it does suggest that microbiome-based prevention can become part of a more resilient, sustainable and forward-looking approach to health. In doing so, it opens a timely conversation on how Europe can better connect food, science, prevention and public policy.